Memphasys (ASX:MEM) Forward Dividend Yield %: 0.00% (As of Jun. 26, 2026)


What is Memphasys Forward Dividend Yield %?

Memphasys ASX:MEM Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. The stock has 5 warning signs investors should review. Among 316 Medical Devices & Instruments companies, Memphasys ranks worse than 316455.38% on this metric.

As of today (2026-06-26), the Forward Annual Dividend Yield of Memphasys is 0.00%.

As of today (2026-06-26), the Trailing Annual Dividend Yield of Memphasys is 0.00%.

ASX:MEM's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.09
* Ranked among companies with meaningful Forward Dividend Yield % only.

Memphasys's Dividends per Share for the six months ended in Dec. 2025 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Memphasys  (ASX:MEM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Memphasys Forward Dividend Yield % Related Terms

ASX:MEM vs ABT, SYK, MDT: Forward Dividend Yield % Comparison

For the Medical Devices subindustry, Memphasys's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Memphasys Forward Dividend Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Memphasys's Forward Dividend Yield % falls into.


Memphasys Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Memphasys (ASX:MEM) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Memphasys and its competitors. According to the industry distribution chart, Memphasys ranks #999999 out of 316 companies in the Medical Devices & Instruments industry.
Is Memphasys' Forward Dividend Yield % too high?
Memphasys' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Memphasys ranks #999999 out of 316 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Forward Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #999999 out of 316 companies for Forward Dividend Yield %. This places Memphasys in the lower half of its industry. The industry median Forward Dividend Yield % is 2.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.09, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Memphasys Business Description

Other Exchanges IG7:Germany
Address 34-36 Richmond Road, Level 1, Homebush West, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.